


The Antithrombin III Content of Cryoprecipitate Prepared from Blood

Collected with and without Heparin

DTIC FILE COPY





T. M. COSGRIFF, L. A. HODGSON AND J. V. WEST

From the Coagulation Laboratory, Division of Medicine, U.S. Army Medical

Research Institute of Infectious Diseases, Fort Detrick, Maryland 21701



Accession For
NTIS GRAZI DIC TAB
Unanmounced Justification
Ву
Distribution/
Availability Codes
Ava-1 and/or Dist Special
A

Footnotes

The views of the authors do not purport to reflect the positions of the Department of the Army or the Department of Defense.

Running title: Cryoprecipitate and Antithrombin III

Abstract

Antithrombin III (AT III) is a plasma protein which acts as the principal inhibitor of thrombin and is a major modulator of intravascular coagulation. Hereditary deficiency of AT III leads to recurrent episodes of thromboembolism. Acquired deficiency of AT III occurs in persons with a variety of conditions, including severe liver disease and disseminated intravascular coagulation. Replacement of AT III may be important in some deficient persons. To determine if cryoprecipitate is a useful source of AT III, we measured the AT III content of cryoprecipitate prepared from citrate phosphate dextrose (CPD) blood using coagulation, fluorogenic, and immunoassays. Using the fluorogenic assay, we also determined the effect of adding heparin to blood on cryoprecipitation of AT III. Functional and antigenic AT III levels were similar to those of normal plasma in all CPD units tested, indicating that AT III is not concentrated in cryoprecipitate. Heparin had no effect on the cryoprecipitation of AT III.

Key Words: Cryoprecipitate, Antithrombin III, Heparin

Introduction

Antithrombin III (AT III) is an α_2 -globulin of plasma which acts as the principal inhibitor of thrombin and other activated procoagulants, such as factor X_a . As heparin cofactor, it accounts for the anticoagulant effect of heparin. Hereditary deficiency of AT III leads to recurrent thromboembolism. Acquired deficiency occurs in a number of conditions, including severe liver disease and disseminated intravascular coagulation (DIC). The latter has been successfully treated by infusion of an AT III concentrate. Such concentrates, however, are not generally available and have not been approved for clinical use.

The purpose of this study was two-fold: first to determine whether cryoprecipitate could serve as a useful source of AT III for replacement therapy in persons with conditions such as DIC, and second to determine whether the addition of heparin to blood at the time of collection would increase the AT III content of cryoprecipitate.

Methods

Blood from ten donors was collected in citrate phosphate dextrose and cryoprecipitate prepared by standard blood bank methods. Blood from three donors was collected into sodium citrate (3.8%), and sodium citrate plus heparin (169 U/mg of protein) (Sigma Chemical Co., St. Louis, MO.). Blood from one of these donors was also collected into heparin alone.

AT III activity was measured by coagulation (Ortho Diagnostics, Raritan, NJ.), and fluorogenic (Dade Division, American Hospital Supply Corporation, Miami, FL.) assays. AT III antigen level was measured by radial immunodiffusion (Behring Diagnostics, American Hoechst Corporation, Somerville, NJ.). Factor VIII procoagulant activity was measured by a one-stage coagulation assay.

Results

The AT III concentration as determined by the three different assay methods for each of the ten cryoprecipitates is shown in Table 1. The values for the three assays are comparable and are similar to those found in normal human plasma. Addition of heparin to blood at the time of collection had no effect on the AT III content of cryoprecipitate as measured by the fluorogenic assay (Table 2).

Discussion

In addition to its use as a source of factor VIII, cryoprecipitate is often used to replace fibrinogen. Of More recently, it has been used as a source of fibronectin to correct opsonic deficiency in patients with trauma and sepsis. Such patients frequently have DIC as well, and might benefit from AT III replacement. Without adequate levels of AT III, heparin is ineffective.

The results of the present study show that AT III is not concentrated in cryoprecipitate in contrast to factor VIII, fibrinogen and fibronectin. The AT III concentration of cryoprecipitate is essentially the same as that in plasma. The fact that AT III activity and antigenic levels are comparable indicates that the AT III that is present is active. These results extend those of Mintz et al 12 who found similar AT III levels in fresh-frozen plasma, cryoprecipitate and cryoprecipitate-depleted plasma from five normal donors.

Heparin has been reported to increase the precipitation of fibronectin 13 and factor VIII. 14 Because heparin is known to bind to AT III, 3 it was reasonable to determine if it might increase the AT III concentration of cryoprecipitate as well. The results of the present study indicate that this is not the case. The AT III concentration of

cryoprecipitate remained the same as that of plasma when heparin was added to blood at the time of collection in concentrations ranging from 1 to 1000 U/ml.

Until AT III concentrates become available for clinical use fresh-frozen plasma can be used as a convenient source of AT III.

References

- Abildgaard U. Purification of two progressive antithrombins of human plasma. <u>Scand J Clin Lab Invest</u>. 1967;19:190.
- Østerud B, Miller-Andersson M, Abildgaard U, Prydz H. The
 effect of antithrombin III on the activity of the coagulation
 factors VII, IX and X. Thrombos Haemostas. 1976;35:295.
- Rosenberg RD. Actions and interactions of antithrombin and heparin. New Engl J Med. 1975;292:146.
- 4. Egeberg O. Inherited antithrombin deficiency causing thrombophilia.

 Thromb Diath Haemorrh. 1965;13:516.
- 5. von Kaulla E, von Kaulla KN. Antithrombin III and diseases.

 Am J Clin Pathol 1967; 48:69.
- 6. Bick RL, Dukes ML, Wilson WL, Fekete LF. Antithrombin

 III (AT III) as a diagnostic aid in disseminated intravascular coagulation. Thromb Res. 1977;10:721.
- Schipper HG, Kahle LH, Jenkins CSP, ten Cate JW.
 Antithrombin III transfusion in disseminated intravascular coagulation. Lancet. 1978;1:854.
- 8. Technical Manual of the American Association of Blood Banks, 7th ed. Washington, DC, 1977.
- 9. Simone JV, Vanderheiden J, Abildgaard CF. A semiautomatic one-stage factor VIII assay with a commercially prepared standard. J Lab Clin Med. 1967;69:706.
- Ness PM, Perkins HA. Cryoprecipitate as a reliable source of fibrinogen replacement. JAMA. 1979;241:1690.

- 11. Saba, TM, Blumenstock FA, Scovill WA, Bernard H. Cryoprecipitate reversal of opsonic $\alpha 2$ -surface binding glycoprotein deficiency in septic surgical and trauma patients. Science. 1978;201:622.
- 12. Mintz PD, Blatt PM, Kuhns WJ, Roberts HR. Antithrombin III in fresh froze. plasma. cryoprecipitate, and cryoprecipitate-depleted plasma. Transfusion. 1979;19:597.
- 13. Mosesson MW, Umfleet RA. The cold-insoluble globulin of human plasma. I. Purification, primary characterization, and relationship to fibrinogen and other cold-insoluble fraction components. <u>J Biol</u> Chem. 1970;245:5728.
- 14. Rock GA, Cruickshank WH, Tackaberry ES, Palmer DS. Improved vields of factor VIII from heparinized plasma. Vox Sang. 1979;36:294.

Table 1. AT III Activity and Antigen Level and ${
m VIII}_{
m c}$ Activity in 10 Units of CPD Cryoprecipitate,

		AT III Activity	tivity					
Cryoprecipitate	Coagulation Assay	ion Assay	Fluorogenic Assay	ic Assay	AT III Antigen	Antigen	VIII _C 4	VIII _c Activity
No.	%	U/ml	%	U/m1	%	mg/d1	52	U/ml
7	68	6.0	100	1.0	98	24	792	7.9
2	85	6.0	85	6.0	86	24	700	7.0
E	111	1,1	84	8.0	68	25	780	8.4
7	66	1.0	100	1.0	93	26	999	5.6
5	86	1.0	06	6.0	93	26	09	9.0
9	7.1	0.7	78	8.0	68	25	700	4.0
7	86	1.0	96	1.0	93	26	240	2.4
80	86	1.0	105	1.1	93	26	220	2.2
6	89	6.0	06	6.0	98	24	396	4.0
10	101	1.0	95	1.0	96	27	392	3.9
Mean	92.3	1.0	94.0	6.0	90.06	25	394	3.9
SD	8.4	0.1	10.9	0.1	3.7	1.1	199.7	2.0
Normal Range for								
Human Plasma	82-120	0.8-1.2	80-120	0.8-1.2	74-104	17-30	50-150	0.5-1.5

activity, and mg/dl for the immunoassay. Normal activity for AT III and VIII, are taken as $1 \, \mathrm{U/ml}$ Values are given as percent of normal for each assay. U/ml are also given for assays measuring of human plasma.

Table 2. AT III Activity in Cryoprecipitate Obtained from Blood with and without Addition of Heparin

			Codium Ci	trate + Go	coainm Cirrate + Sodium Henarin	11	Sodium Hc	Sodium Heparin Only
Donor	Sodium Citrate Uniy		Sodiam Ci	בדמוב י אי	t the second			
		1 U/m1	5 U/ml	10 U/ml	100 U/m1	1 U/m1 5 U/m1 10 U/m1 100 U/m1 1000 U/m1 1 U/m1 5 U/m1	l U/ml	5 U/ml
1								
Cryoprecipitate	115	120		120	96	76	95	95
Plasma	120							
2								
Cryoprecipitate	114			107				
Plasma	103							
3								
Cryoprecipitate	92		82					
Plasma	96							

Values are percent of normal activity for the fluorogenic assay. The normal range for human plasma is 80-120%. Sodium heparin concentration is in units/ml blood. SECURITY CLASSIFICATION OF THIS PAGE (When Date Entered)

REPORT DOCUMENTATION PAGE	READ INSTRUCTIONS BEFORE COMPLETING FORM	
1. REPORT NUMBER 2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER	
4D-A114 9	508	
4. TITLE (and Substitle) THE ANTITHROMBIN III CONTENT OF CRYOPRECIPITATE PREPARED FROM BLOOD COLLECTED WITH AND WITHOUT	5. TYPE OF REPORT & PERIOD COVERED	
HEPARIN	6. PERFORMING ORG. REPORT NUMBER	
7. AUTHOR(s) Thomas M. Cosgriff	8. CONTRACT OR GRANT NUMBER(*)	
Loreen A. Hodgson James V. West		
9. PERFORMING ORGANIZATION NAME AND ADDRESS US Army Medical Research Institute of	10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS	
Infectious Diseases Fort Detrick, Frederick, Maryland 21701	871-BC-142	
11. CONTROLLING OFFICE NAME AND ADDRESS US Army Medical Research and Development Command	12. REPORT DATE April 8, 1982	
Office of the Surgeon General Department of the Army, Washington, DC 20314	13. NUMBER OF PAGES 11	
14. MONITORING AGENCY NAME & ADDRESS(If different from Controlling Office)	15. SECURITY CLASS. (of this report)	
	Unclassified	
	15a. DECLASSIFICATION/DOWNGRADING SCHEDULE	
16. DISTRIBUTION STATEMENT (of this Report)		
Approved for public release; distribution unlimited		
17. DISTRIBUTION STATEMENT (of the ebstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
Submitted for publication to the journal <u>Transfusion</u> .		
19. KEY WORDS (Continue on reverse eide if necessary and identify by block number) cryoprecipitate antithrombin III heparin		
Antithrombin III (AT III) is a plasma protein which acts as the principal inhibitor of thrombin and is a major modulator of intravascular coagulation. Hereditary deficiency of AT III leads to recurrent episodes of thromboembolism. Acquired deficiency of AT III occurs in persons with a variety of conditions,		

including severe liver disease and disseminated intravascular coagulation. Replacement of AT III may be important in some deficient persons. To determine if cryoprecipitate is a useful source of AT III, we measured the AT III content of cryoprecipitate prepared from citrate phosphate dextrose (CPD) blood using

DD 1 JAN 73 1473 EDITION OF F NOV 65 IS OBSOLETE

UNCE SEFIE 0 5 1 7

SECURITY CLASSIFICATION OF THIS PAGE (Moon Date Ente

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE(When Date Entered)

Block 20: ABSTRACT (continued)

coagulation, fluorogenic, and immunoassays. Using the fluorogenic assay, we also determined the effect of adding heparin to blood on cryoprecipitation of AT III. Functional and antigenic AT III levels were similar to those of normal plasma in all CPD units tested, indicating that AT III is not concentrated in cryoprecipitate. Heparin had no effect on the cryoprecipitation of AT III.

UNCLASSIFIED

